- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02308332
Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning (ESCAPE)
Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning, ESCAPE Study
Study Overview
Status
Intervention / Treatment
Detailed Description
Efavirenz, an antiretroviral drug used for the treatment of human immunodeficiency virus 1 (HIV-1) infections, is known for its neurological and psychiatric adverse events. Efavirenz is part of Atripla®, a single tablet regimen (STR), currently the most prescribed antiretroviral drug in the Netherlands. Recently, a new STR has become available, Eviplera® containing a successor of Efavirenz, named Rilpivirin. It has been shown in the phase-3 ECHO and THRIVE studies that Atripla as well as Eviplera have excellent and comparable antiretroviral efficacy in naive HIV-infected patients. Furthermore, data from these studies have shown that Eviplera was associated with fewer neurological and psychiatric adverse events than Atripla over 48 weeks. However, this was only patient reported adverse events, not neuropsychological evaluation. Furthermore, they were treatment naïve for HIV. Moreover, there might be a bias in these kind of switch studies due to the fact that those patients who switch will mostly regard their new combination better than the old one. Contrary, data on the long term impact of Efavirenz on neuropsychological performance and symptoms are conflicting.
Objective: This study aims to investigate the effect of switching from Atripla to Eviplera on neurocognitive performances (neurocognitive testing) and imaging (functional MRI scanning) in virologically suppressed HIV-infected patients.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Utrecht, Netherlands
- UMC Utrecht
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male, between 30 and 50 years
- HIV-1 RNA < 50 copies/mL on screening visit
- on Atripla continuously for ≥6 months preceding the screening visit
- Have a HIV genotype prior to starting cART with Atripla with no known resistance to any of the study agents at any time in the past including, but not limited to RT mutations K65R, K101E/P, E138G/K/Q/R, Y181C/I/V, M184V/I and H221Y
- Negative TPHA or VDRL < 12 months prior to the screening visit
- no signs of an acute or chronic hepatitis C infection within the past 12 months before screening as defined in the Dutch guideline (Arends et al. Neth J Med 2011)
- No subjective neurocognitive complaints in the preceding 12 months
- willingness to take Eviplera together with food according to the manufacturer's prescriptions.
- Estimated glomerular filtration rate ≥50 mL/min (Cockcroft-Gault formula) on last routine measurement during outpatient clinic
- able to understand and comply to study procedures and to provide written informed consent
Exclusion Criteria:
- Non-native Dutch speakers
- Proven major depression through psychiatric consultation within the past year or on anti-depressant drugs (SSRI or TCA)
- Active or known from medical history past CNS opportunistic infections
- History of proven neurologic disease (e.g. multiple sclerosis, brain tumor, cerebrovascular event, etc)
- Active psychiatric disorders classified according to the DMS V criteria
- History or evidence of alcohol or drug abuse defined according to DSM V criteria
- TSH within normal reference values on last routine measurement during outpatient clinic
- Contraindications for undergoing an MRI; a pacemaker or metallic devices/foreign bodies in situ, proven claustrophobia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intervention
patients switching from Atripla to Eviplera
|
switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
Other Names:
|
No Intervention: Control
patients remaining on Atripla
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the neurocognitive performance as measured by neuropsychological test composite score after 12 weeks in stable HIV-infected patients switched from Atripla to Eviplera compared to a control group of patients on Atripla.
Time Frame: 12 weeks
|
Patients will undergo a neuropsychological test battery where multiple standardized test will be undertaken to assess 7 different domains; Verbal Fluency, Executive Functioning, Speed of Information Processing, Learning, Memory, Attention/Working Memory, Motor skills.
Raw scores can be calculated per domain and as a composite score.
Differences in mean changes in composite score between baseline and end of study will be assessed with a paired T-test.
A p-value <0.05 will be considered statistically significant.
Within-arm changes will be assessed using Wilcoxon signed rank tests, and between-group comparisons will be evaluated with Wilcoxon rank sum tests.
Multivariate analyses will be performed to analyse differences in the primary endpoints between the study groups.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
to assess the correlation between neurocognitive improvement (neuropsychological evaluation) and functional imaging (fMRI) after switching Atripla to Eviplera
Time Frame: 12 weeks
|
The aim is to investigate if there is a correlation between improvement on neuropsychological test scores after 12 weeks of Eviplera therapy, and changes on fMRI after 12 weeks of Eviplera therapy.
If there is a correlation, that means fMRI could be used to evaluate neurocognitive decline.
Basically, we will asses if there is a correlation between ∆neuropsychological score and ∆fMRI-score.
Because this is ordinal data, we will use a Spearman rank-order correlation to calculate a correlation-coefficient.
|
12 weeks
|
to evaluate correlation between neurocognitive performance and health related quality of life measured by SF-36 total score after switching from Atripla to Eviplera.
Time Frame: 12 weeks
|
The aim is if an improvement in neuropsychological test scores after 12 weeks of Eviplera therapy is correlated with an improvement of quality of life.
Basically, we will assess if there is a correlation between ∆neuropsychological score and ∆SF-36 total score.
Because this is ordinal data, we will use a Spearman rank-order correlation to calculate a correlation-coefficient.
|
12 weeks
|
to assess the emotional functioning measured by HADS total score after switching Atripla to Eviplera by using a paired T-test to calculate differences in mean changes between baseline and end of study
Time Frame: 12 weeks
|
12 weeks
|
|
to assess USER-P (total scores) after switching Atripla to Eviplera
Time Frame: 12 weeks
|
12 weeks
|
|
to assess drug levels of Efavirenz (as a component of Atripla) and Rilpivirin (as a component of Eviplera) in relation to changes in neurocognitive performance and fMRI in both patient groups.
Time Frame: 12 weeks
|
With this study, we want to investigate the effect of switching Efavirenz (as a component of Atripla) to Rilpivirine (as a component of Eviplera) on neurocognition.
Our hypothesis is that neurocognition (as measured by neuropsychological testing scores) will improve when switching from Efavirenz (as a component of Atripla).
If that is the case, hypothetically a lower or higher drug level of Efavirenz (as a component of Atripla) could have an effect on neurocognition (as measured by neuropsychological test scores).
We will assess the correlation between drug level of Efavirenz or Rilpivirine and changes in neurocognitive function as measured by neuropsychological testing, and fMRI changes by regression analyses using drug levels as an independent variable and neuropsychological test scores as a dependent variable.
|
12 weeks
|
to evaluate the usefulness of PROMIS instruments in HIV research
Time Frame: 12 weeks
|
In our study, we will use the PROMIS instruments Anxiety, Depression, Sleep disturbance and Satisfaction with social roles and activities.
These are all short forms containing 8 questions or statements.
Patients are asked to rate the questions from 1-5 into which extent they believe them to be true; 1 being not at all and 5 being very much.
For each short form, a score will be calculated by adding the values of the response to each question.
PROMIS provides a score conversion table where the score can be translated into a T-score.
This rescales the patient's score into a standardized score with a mean of 50 and a standard deviation of 10.
In order to provide these results, PROMIS uses a calibration sample containing data from over 21000 respondents.
Differences in mean changes between baseline and end of study, as well as between the two study groups will be calculated using a paired T-test.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Joop Arends, MD PhD, UMC Utrecht
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABR50959
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Associated Neurocognitive Disorder
-
St Vincent's Hospital, SydneyUnknownHIV | HIV-associated Neurocognitive Disorder (HAND)Australia
-
GCS IHFB Cognacq-JayHospital Ambroise Paré ParisCompletedHIV-1-infection | HIV Associated Neurocognitive DisorderFrance
-
East Tennessee State UniversityNeuronetrix, Inc.CompletedHIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND)United States
-
University of CalgaryCanadian Institutes of Health Research (CIHR); University of Alberta; Epidemiology...TerminatedHIV Associated Neurocognitive Disorder (HAND)Canada
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)CompletedHIV Associated Neurocognitive DisorderUnited States
-
Massachusetts General HospitalMerck Sharp & Dohme LLCCompletedHIV | Neurotoxicity | HIV-associated Neurocognitive DisorderUnited States
-
Posit Science CorporationCompletedHIV-associated Neurocognitive DysfunctionUnited States
-
Fundació Institut de Recerca de l'Hospital de la...Hospital Clinic of Barcelona; University of BarcelonaCompletedHIV-associated Hypertriglyceridemia | HIV-associated Hypercholesterolemia | HIV-associated Inflammatory StateSpain
-
Johns Hopkins UniversityMakerere UniversityTerminatedHIV Infections | HIV-associated Cognitive ImpairmentUganda
-
Yale UniversityNational Institute of Mental Health (NIMH); National Institutes of Health (NIH)RecruitingHealthy | HIV Dementia | HIV Associated Neurocognitive Disorder | HIV EncephalitisUnited States
Clinical Trials on Eviplera
-
St Stephens Aids TrustCompleted
-
Azienda Ospedaliera San Gerardo di MonzaGilead SciencesCompletedQuality of Life | HIV-1 Infection | Impaired Cognition | Poor Quality Sleep | Depression/AnxietyItaly
-
Andrew CarrCompletedHIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With MenAustralia
-
St Stephens Aids TrustGilead SciencesCompleted
-
Gilead SciencesCompleted
-
Gilead SciencesCompletedHIV-1 InfectionUnited States, Spain, United Kingdom, Canada, Puerto Rico, France, Belgium, Italy, Germany, Austria
-
Gilead SciencesCompletedHIV-1 InfectionUnited States, Spain, United Kingdom, Netherlands, Germany, Canada, Sweden, Switzerland, Italy, Belgium, Puerto Rico, France
-
Gilead SciencesCompletedHIV-1 InfectionCanada, United States, Puerto Rico, Spain, United Kingdom, France, Portugal, Netherlands, Belgium, Italy, Australia, Austria, Germany, Switzerland
-
Hospital Universitari Vall d'Hebron Research InstituteGilead SciencesCompleted
-
Sheba Medical CenterTerminated